Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease

Table 4 Comparison of study population using the fibrosis-8 score for predicting significant fibrosis (F ≥ 2)

Variable	Data from AASLD 2019, n = 522	FIB-8 score validation (EASL 2020), n = 130	FIB-8 score validation (Our cohort), n = 511
Population	Mean age: 49 ± 12. Female: 62.5%; BMI: 34 ± 7 kg/m2; DM: 30%; ≥ F2: 52.5%	Mean age: 52.4; Female: 53.1%; BMI: 31.5 kg/m2; DM: 34%; ≥ F2: 35.4%	Mean age: 49.3 ± 11.9; Female: 53.0%; BMI: 30.4 ± 7.1 kg/m2; DM: 52.4%; ≥ F2: 30.7%
Sensitivity and specificity %	86.7% and 82.7%, respectively, Validation set	> 90%, 80.6%	92.3%, 67.5%
AUC for predicting > F2 fibrosis	0.78, Validation set	0.84	0.77
Performance superior to	> FIB-4 score; P < 0.001; > NFS; P = 0.005	> FIB-4 score (AUC 0.80); > NFS (AUC 0.77)	> FIB-4 score; P = 0.073; > NFS; P = 0.001

NAFLD: Nonalcoholic fatty liver disease; FIB-8: Fibrosis-8 score; FIB-4: Fibrosis-4 score; NFS: NAFLD fibrosis score; AASLD: American Association for the Study of Liver Diseases; EASL: European Association for the Study of the Liver; AUROC: Areas under the receiver operating characteristic curves; BMI: Body mass index; DM: diabetes mellitus.